Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel Free VRCI Stock Alerts

Verici Dx (VRCI) Competitors

Verici Dx logo
GBX 0.20 -0.02 (-10.67%)
As of 09/15/2026 11:53 AM Eastern
Compare

VRCI vs. YGEN, AGL, GENI, PRM, and IDHC

Should you buy Verici Dx stock or one of its competitors? Verici Dx's main competitors and comparable companies include Yourgene Health (YGEN), ANGLE (AGL), GENinCode (GENI), Proteome Sciences (PRM), and Integrated Diagnostics (IDHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Verici Dx compare to Yourgene Health?

Verici Dx (LON:VRCI) and Yourgene Health (LON:YGEN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Verici Dx has a beta of 1.222, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Yourgene Health has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Yourgene Health has a net margin of -27.55% compared to Verici Dx's net margin of -193.05%. Yourgene Health's return on equity of -27.06% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-193.05% -138.93% -26.14%
Yourgene Health -27.55%-27.06%-6.71%

In the previous week, Yourgene Health's average media sentiment score of 0.00 beat Verici Dx's score of -1.31 indicating that Yourgene Health is being referred to more favorably in the news media.

Company Overall Sentiment
Verici Dx Negative
Yourgene Health Neutral

Verici Dx has higher earnings, but lower revenue than Yourgene Health. Verici Dx is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.66M1.25-£6.56M-£0.90N/A
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A

15.9% of Verici Dx shares are held by institutional investors. Comparatively, 23.3% of Yourgene Health shares are held by institutional investors. 1.2% of Verici Dx shares are held by insiders. Comparatively, 64.4% of Yourgene Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Yourgene Health beats Verici Dx on 8 of the 11 factors compared between the two stocks.

How does Verici Dx compare to ANGLE?

ANGLE (LON:AGL) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

17.5% of ANGLE shares are owned by institutional investors. Comparatively, 15.9% of Verici Dx shares are owned by institutional investors. 2.7% of ANGLE shares are owned by insiders. Comparatively, 1.2% of Verici Dx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, ANGLE had 1 more articles in the media than Verici Dx. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for Verici Dx. ANGLE's average media sentiment score of 0.00 beat Verici Dx's score of -1.31 indicating that ANGLE is being referred to more favorably in the media.

Company Overall Sentiment
ANGLE Neutral
Verici Dx Negative

Verici Dx has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANGLE£2.62M2.89-£21.76M-£4.80N/A
Verici Dx£3.66M1.25-£6.56M-£0.90N/A

ANGLE has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.222, indicating that its stock price is 22% more volatile than the broader market.

Verici Dx has a net margin of -193.05% compared to ANGLE's net margin of -1,444.04%. Verici Dx's return on equity of -138.93% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
ANGLE-1,444.04% -191.36% -29.89%
Verici Dx -193.05%-138.93%-26.14%

Summary

Verici Dx beats ANGLE on 8 of the 13 factors compared between the two stocks.

How does Verici Dx compare to GENinCode?

GENinCode (LON:GENI) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

GENinCode has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.222, meaning that its stock price is 22% more volatile than the broader market.

GENinCode has a net margin of -185.47% compared to Verici Dx's net margin of -193.05%. Verici Dx's return on equity of -138.93% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
GENinCode-185.47% -409.40% -63.99%
Verici Dx -193.05%-138.93%-26.14%

11.4% of GENinCode shares are owned by institutional investors. Comparatively, 15.9% of Verici Dx shares are owned by institutional investors. 8.4% of GENinCode shares are owned by company insiders. Comparatively, 1.2% of Verici Dx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, GENinCode's average media sentiment score of 0.00 beat Verici Dx's score of -1.31 indicating that GENinCode is being referred to more favorably in the media.

Company Overall Sentiment
GENinCode Neutral
Verici Dx Negative

GENinCode has higher earnings, but lower revenue than Verici Dx. GENinCode is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GENinCode£3.08M2.08-£6.10M-£2.08N/A
Verici Dx£3.66M1.25-£6.56M-£0.90N/A

Summary

Verici Dx beats GENinCode on 7 of the 12 factors compared between the two stocks.

How does Verici Dx compare to Proteome Sciences?

Verici Dx (LON:VRCI) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

In the previous week, Proteome Sciences had 3 more articles in the media than Verici Dx. MarketBeat recorded 3 mentions for Proteome Sciences and 0 mentions for Verici Dx. Proteome Sciences' average media sentiment score of 0.00 beat Verici Dx's score of -1.31 indicating that Proteome Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Verici Dx Negative
Proteome Sciences Neutral

Proteome Sciences has a net margin of -81.50% compared to Verici Dx's net margin of -193.05%. Proteome Sciences' return on equity of 33.80% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-193.05% -138.93% -26.14%
Proteome Sciences -81.50%33.80%-19.25%

Proteome Sciences has higher revenue and earnings than Verici Dx. Proteome Sciences is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.66M1.25-£6.56M-£0.90N/A
Proteome Sciences£3.76M1.28-£4.08M-£1.04N/A

Verici Dx has a beta of 1.222, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.157, suggesting that its share price is 84% less volatile than the broader market.

15.9% of Verici Dx shares are owned by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are owned by institutional investors. 1.2% of Verici Dx shares are owned by company insiders. Comparatively, 36.7% of Proteome Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Proteome Sciences beats Verici Dx on 9 of the 13 factors compared between the two stocks.

How does Verici Dx compare to Integrated Diagnostics?

Verici Dx (LON:VRCI) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Verici Dx has a beta of 1.222, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, indicating that its stock price is 57% less volatile than the broader market.

15.9% of Verici Dx shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 1.2% of Verici Dx shares are held by company insiders. Comparatively, 78.4% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Integrated Diagnostics has a net margin of 16.49% compared to Verici Dx's net margin of -193.05%. Integrated Diagnostics' return on equity of 39.61% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-193.05% -138.93% -26.14%
Integrated Diagnostics 16.49%39.61%9.69%

Integrated Diagnostics has higher revenue and earnings than Verici Dx. Verici Dx is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.66M1.25-£6.56M-£0.90N/A
Integrated Diagnostics£9.17B0.00£4.01T£250.030.00

In the previous week, Integrated Diagnostics had 1 more articles in the media than Verici Dx. MarketBeat recorded 1 mentions for Integrated Diagnostics and 0 mentions for Verici Dx. Integrated Diagnostics' average media sentiment score of 0.00 beat Verici Dx's score of -1.31 indicating that Integrated Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Verici Dx Negative
Integrated Diagnostics Neutral

Summary

Integrated Diagnostics beats Verici Dx on 10 of the 13 factors compared between the two stocks.

Get Verici Dx News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRCI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

VRCI vs. The Competition

Export
MetricVerici DxLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£4.60M£9.85B£7.21B£2.88B
Dividend YieldN/A1.47%2.57%6.26%
P/E Ratio-0.2268.77272.90366.53
Price / Sales1.25107.65708.3990,145.12
Price / Cash1.3126.2377.7127.89
Price / Book0.055.4310.466.43
Net Income-£6.56M£56.67B£3.49B£5.89B
7 Day Performance0.50%1.06%-0.76%-0.30%
1 Month Performance-18.95%1.04%-0.39%-0.59%
1 Year Performance-66.50%25.47%18.93%20.21%

Verici Dx Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRCI
Verici Dx
N/AGBX 0.20
-10.7%		N/A-62.8%£4.60M£3.66MN/A19
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253
AGL
ANGLE
N/AGBX 2.35
-11.3%		N/A-25.4%£7.58M£2.62MN/A650
GENI
GENinCode
N/AGBX 0.95
-0.5%		N/A-42.1%£7.15M£3.08MN/A2,300
PRM
Proteome Sciences
N/AGBX 1.55
flat		N/A-60.6%£5.44M£3.76MN/A240

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:VRCI) was last updated on 9/16/2026 by MarketBeat.com Staff.
From Our Partners
“This is the Perfect Tech Stock”
Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...
Brownstone Research | Sponsoredtc pixel
Jon Najarian's #1 Energy Trade for 2026
Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...
Banyan Hill Publishing | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The national debt just passed $39 trillion
The U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...
US Gold Bureau | Sponsoredtc pixel
You’ve never seen anything like this before
For centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
What Is A Roth Conversion, And How Do I Set One Up?
A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...
SmartAsset | Sponsoredtc pixel